LEF1 (C12A5) Rabbit mAb (Alexa Fluor® 647 Conjugate) detects endogenous level of total LEF1 protein. It does not recognize the dominant negative forms of LEF1 generated by an alternative promoter.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro82 of human LEF1.
Description
This Cell Signaling Technology antibody is conjugated to Alexa Fluor®647 fluorescent dye and tested in-house for direct flow cytometry analysis in human cells. The antibody is expected to exhibit the same species cross-reactivity as the unconjugated LEF1 (C12A5) Rabbit mAb #2230
原厂资料:
Specificity / Sensitivity
LEF1 (C12A5) Rabbit mAb (Alexa Fluor® 647 Conjugate) detects endogenous level of total LEF1 protein. It does not recognize the dominant negative forms of LEF1 generated by an alternative promoter.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro82 of human LEF1.
Description
This Cell Signaling Technology antibody is conjugated to Alexa Fluor®647 fluorescent dye and tested in-house for direct flow cytometry analysis in human cells. The antibody is expected to exhibit the same species cross-reactivity as the unconjugated LEF1 (C12A5) Rabbit mAb #2230
Background
LEF1 and TCF are members of the high mobility group (HMG) DNA binding protein family of transcription factors that consists of the following: Lymphoid Enhancer Factor 1 (LEF1), T Cell Factor 1 (TCF1), TCF3, and TCF4 (1). LEF1 and TCF1 were originally identified as important factors regulating early lymphoid development (2) and act downstream in Wnt signaling. LEF1 and TCF bind to Wnt response elements to provide docking sites for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1 and TCF are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers including colon cancer (4,5).
LEF1 has several isoforms due to alternative splicing. LEF1 also has an alternative promoter that is preferentially active in lymphocytes. The isoforms generated by this alternative promoter have no amino-terminal β-catenin binding domain and may function in a dominant negative manner (6-8)
Storage: Supplied in PBS (pH 7.2), less than 0.1% sodium
azide and 2 mg/ml BSA. Store at 4°C. Do not aliquot the
antibody. Protect from light. Do not freeze.